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costs. In this model, prescription non-procurement was
more likely to be reported in the Medicare-only popula-
tion (OR: 1.47; 95% CI 1.46–1.48) and in the Medicare
plus Medicaid population (OR: 1.11; 95% CI 1.10–1.12)
as compared to respondents with Medicare plus private
insurance coverage. CONCLUSIONS: Signiﬁcantly dif-
ferent rates of persons who forego ﬁlling a prescription
for cost reasons were observed among Medicare beneﬁ-
ciaries. More vulnerable groups of seniors were identiﬁed.
Dual eligible Medicare/Medicaid enrollees and those with
Medicare alone are more likely to restrict medication 
procurement due to cost.
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OBJECTIVES: 1) To explore 1-year persistence pattern
of Overactive Bladder/Urinary Incontinence (OAB/UI)
medication treatment; 2) to discover factors associated
with persistence; and 3) to investigate the beneﬁt of reﬁll
adherence on urinary track infection (UTI). METHODS:
Retrospective analyses on continuously enrolled adult
patients diagnosed with OAB/UI and received at least one
OAB/UI medication from July 1999 to April 2001 (with
6-month run-in period and 1-year follow-up period) are
employed. Time to discontinuity, deﬁned as the period
from the index date to the discontinuity date (when any
medication-uncovered interval is longer than 30 days), 
is used to describe the persistence pattern of patients.
Adherence is measured by medication possession ratio
(MPR). A Cox Proportional Hazard model is applied to
reveal risk factors of non-persistence. A logistic regression
is used to examine the relationship of those same factors
with reﬁll adherence and to assess the effect of adherence
on UTI incidence rate. RESULTS: Of 6518 eligible
patients, 26.8% have only 1 prescription. 5751 patients
(88.2%) discontinue within the following year, among
which, 92.2% fail to continue treatment after 183 days.
Only 952 patients (14.6%) exhibit good adherence (MPR
>= 0.8). The mean MPR of the whole cohort is 0.39 and
the median is 0.24. Signiﬁcant predictors of higher per-
sistence include Caucasians, 75 years old or above, prior
medication use, and initiating extended-release form of
drug. Patients with prior prescription of antidepressant or
diagnosis of depression show lower persistence. Similar
results are found for adherence. Logistic regression indi-
cates that good reﬁll adherence reduces the risk of being
diagnosed with UTI by 33% in the post-treatment period
(P = 0.0008, OR = 0.672). CONCLUSIONS: Both 
persistence of OAB/UI medication and reﬁll adherence 
are low, suggesting the need to develop effective inter-
ventions in OAB/UI and UTI.
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OBJECTIVES: Medication non-compliance has been a
growing concern for healthcare management and can
result in progression of cardiovascular disease (CV) and
an increase in economic burden. To develop models to
predict the risk for future medication non-compliance
among patients with hypertension and hyperlipidemia.
METHODS: Two predictive models were constructed
using pharmacy and medical claims from 2380 patients
newly treated with anti-hypertensive medications and
3387 patients newly treated with statins in a managed
care setting. The outcomes of interest were the future
medication compliance rates for both disease states over
a one-year follow-up period. The potential predictors of
compliance included patient characteristics such as age,
gender, type of insurance plan, Chronic Disease Score
(CDS), presence of select comorbidities, copayments,
total medication burden, hospital encounters, outpatient
physician encounters, and initial compliance (0–3 months
of therapy immediately before the follow-up period).
Linear regression models were applied to construct the
models. Each population was randomly split by a 2 to 1
ratio to facilitate spilt-sample validation of the models.
RESULTS: Based on the hypertension model, age, gender,
total co-payments, total medication burden, and initial
compliance showed signiﬁcant relationship with compli-
ance (R2 = 0.45). Based on the hyperlipidemic model, age,
gender, presence of a second CV condition (e.g. angina),
outpatient physician encounters, co-payments at drug ini-
tiation, total medication burden, and initial compliance
demonstrated signiﬁcant relationship with compliance
(R2 = 0.43). In both populations, initial compliance was
the strongest predictor of sustained compliance. CON-
CLUSION: These models can serve as a useful tool to
guide providers in promoting medication compliance.
Both models suggest that assisting the patient to establish
compliant behavior within the ﬁrst three months of a new
treatment regimen can signiﬁcantly inﬂuence sustained
medication adherence with CV medications.
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OBJECTIVES: Long-term continuous use of HMG-CoA
inhibitors (statins) has been shown to be beneﬁcial to
patients with coronary artery disease in several large clin-
ical trials. This study demonstrates a promising model 
to assess the relationship between medication adherence
with statins and the risk of adverse event (hospitalization
or emergency visit) in a managed care population.
METHODS: Conventional outcomes assessments for
medication compliance often encounter the problem of
identifying the causal relationship between adherence and
outcomes (e.g., adverse event). It is not unusual that med-
ication discontinuation occurs after and possibly due to
a hospitalization event. To determine the strength of the
relationship between statin adherence and risk of hospi-
talization, a Cox proportional hazard model was devel-
oped with the time-varying variable deﬁned as proportion
of days covered by statins (PDC) as of the date of ﬁrst
adverse event. For censored subjects, PDC was chosen as
of the end of study period or the date of disenrollment,
whichever occurred ﬁrst. 68,974 adult patients were 
identiﬁed as new statin starters during a 2-year period
from June 1998 to June 2000. Other covariates included
demographics, payer types, previous drug, medical and
procedure uses, and comorbidities. RESULTS: The time
varying covariate (PDC) was the second most signiﬁcant
predictor of time to adverse event (chi-square < 1610.9,
p < 0.0001). The most signiﬁcant predictor of an adverse
event was the existence of a previous adverse event (chi-
square = 2043.1, p < 0.0001). Patients with higher age,
comorbidities and previous high utilization have higher
risk. In addition, patients in HMO and POS have signiﬁ-
cant lower risk than patients with FFS and PPO. CON-
CLUSIONS: Time-varying PDC is one of the strongest
predictors of the risk of an adverse event. Persistence is
signiﬁcantly associated with lower risk of occurrence of
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OBJECTIVE: The purpose of this study is to determine
if there is a relationship between product innovativeness
and direct-to-consumer advertisement. METHODS:
Products advertised directly to the consumer (DTC) were
divided into two categories using the FDA therapeutic
and chemical classiﬁcation system. New molecular enti-
ties and products with priority reviews were classiﬁed as
‘innovative’; all other standard review products were clas-
siﬁed as ‘standard’. Information on product classiﬁcation
and the total number of products approvals was obtained
from FDA prescription drug approval data. The amount
spent on DTC advertising between 1997 and 2001 was
obtained from published data. Products with less than a
0.1% share of annual DTC expenditures were excluded,
as were products launched before 1990, and vaccines 
and biotech products. The average annual expenditure on
DTC advertisement from 1997–2001 was calculated for
each product. Data were analyzed using chi-square and
t-tests. RESULTS: The inclusion criteria were met by 106
distinct products. The proportion of products advertised
in the innovative group was signiﬁcantly higher than the
standard group (p < 0.006). Innovative products are 1.7
times more likely to be advertised directly to the con-
sumer than the standard products. There was no statisti-
cal difference in the average annual DTC expenditure per
product in each group (p = 0.63). CONCLUSION: Inno-
vative products are more likely to be advertised directly
to the consumer which may increase patients’ request for
those medications. This information may help decision
makers understand potential product demand during the
formulary decision making process.
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OBJECTIVE: The purpose of this study was to describe
the economic impact of generic ﬂuoxetine entry on trends
in utilization and costs of new generation antidepressants
(Celexa®, Effexor®, Luvox®, Paxil®, Prozac®, and
Zoloft®) within the Texas Medicaid Program. Addition-
ally, diffusion of market share among generic manufac-
turers following the 180-day marketing exclusivity period
was also examined. METHODS: Retrospective prescrip-
tion claims data from January 2001 through August 2002
were analyzed. Claims were grouped across study agents:
1) Prozac®, 2) ﬂuoxetine, and 3) other (Celexa®,
Effexor®, Luvox®, Paxil®, and Zoloft®) antidepres-
sants. Costs were based on payments to pharmacies.
RESULTS: A total of 1,154,565 prescription claims were
analyzed. Prior to the introduction of generic ﬂuoxetine,
market share for Prozac® was 19.0% (10,754 claims) in
July 2001. In August 2002, market share for Prozac®
decreased to 2.2% (1,479 claims), of which, 952 claims
(64.3%) were for the Prozac® 20mg weekly dose, while
market share for “other antidepressants” grew to 86.7%
(57,259 claims). Generic ﬂuoxetine market share was
11.0% (7,281 claims) in August 2002. Within the generic
ﬂuoxetine market, manufacturers with exclusivity experi-
enced a decrease in market share from 100.0% (7,184
claims) in January 2002 to 63.6% (4,629 claims) in
August 2002. The estimated average payment per unit
(post-rebate) for Prozac® 20mg capsules prior to its
patent expiration (January–July 2001), during the 180-
day generic exclusivity period (August 2001–January
